Title: Revolutionary In-Ovo Vaccine Cuts Chick Crippling Disease by Over 50%
In a groundbreaking discovery, researchers at the University of Arkansas have developed an in-ovo vaccine that significantly reduces bacterial chondronecrosis with osteomyelitis (BCO), also known as hip joint necrosis, in poultry. This innovative vaccine, delivered in a single dose, targets multiple bacterial strains, offering a promising solution to this debilitating disease.
Understanding BCO
BCO occurs when damage to a bird’s gut allows bacteria to permeate and infect the bones in the legs, leading to lameness and eventually crippling. Symptoms typically appear between 30 to 40 days post-hatch, but birds become susceptible to the disease before they hatch. Problematically, meat chickens only start exhibiting this limpness later in their development.
Several bacterium strains can cause BCO, with Staphylococcus, Enterococcus, and E. coli being the most common. Therefore, any effective BCO vaccine must safeguard against multiple bacterial strains. According to American researchers, this crippling condition affects 3 to 5% of the broiler industry, resulting in annual losses of €80 to €100 million in the U.S. alone, due to the rejection of affected chicken breasts.
eBeam Technology: A New Vaccination Approach
The research team utilized the eBeam technology for in-ovo vaccinations. This method generates an electron beam akin to gamma or X-ray radiation, specifically targeting bacterial DNA while preserving essential proteins and epitopes (antigenic determinants needed for an immune response).
When these irradiated bacteria are injected into the egg, the embryo recognizes them as foreign invaders and initiates an immune response. Upon hatching, the chicks already have an immune reaction against those bacterial strains. The study, funded by the US Poultry & Egg Association (USPOULTRY), demonstrated that this vaccination method reduced lameness by over 50%.
Looking Ahead
The success of this in-ovo vaccine paves the way for future enhancements. Plans are underway to incorporate additional bacterial strains to further boost its efficacy. By targeting BCO at its source—the egg—the scientific community is inching closer to eradicating this economically damaging chicken disease.
